diabetes treatments

Google has partnered up with French pharmaceutical company Sanofi to develop new ways of monitoring and treating diabetes.

Diabetes treatments accounted for 21 per cent of Sanofi’s revenue in 2014. The company are known for their medicinal products such as Lantus (insulin glargine) and Lyxumia (lixisenatide).

The collaboration will pair Sanofi’s expertise in diabetes treatments – particularly, insulin – with Google’s Life Sciences division, which is working on devices that can continuously collect diabetes-related data.

The aim of the partnership is that information such as blood glucose levels, HbA1c and medication regimens will be obtained through new technology which can improve diabetes management and reduce the risk of complications.

Andrew Conrad, CEO of the Google Life Sciences, said: “With Sanofi, we can complete the picture of how diabetes unfolds and try to interrupt that development through a proactive and preventive approach.”

Worldwide partnerships

This partnership is the most recent of several collaborations around the world aimed at improving the technology available for diabetes patients.

Last month, Sanofi announced that they will be working with Evotec to ultimate remove the need for diabetes patients to inject insulin.

Google Life Sciences, meanwhile, teamed up with DexCom to develop a new generation of continuous glucose monitors (CGMs) that are smaller and reduce costs of diabetes care.

A contact lens that can track blood glucose levels is also being developed by Google Life Sciences through an existing partnership with Novartis.